Mechanical characterization and cytocompatibility of linoleic acid modified bone cement for percutaneous cement discoplasty.

Minimally invasive spine treatments have been sought after for elderly patients with comorbidities suffering from advanced degenerative disc disease. Percutaneous cement discoplasty (PCD) is one such technique where cement is injected into a degenerated disc with a vacuum phenomenon to relieve patients from pain. Adjacent vertebral fractures (AVFs) are however an inherent risk, particularly for osteoporotic patients, due to the high stiffness of the used cements. While low-modulus cements have been developed for vertebroplasty through the addition of linoleic acid, there are no such variations with a high-viscosity base cement, which is likely needed for the discoplasty application. Therefore, a low-modulus polymethyl methacrylate was developed by the addition of 12%vol. linoleic acid to a high-viscosity bone cement (hv-LA-PMMA). Initial experimental validation of the cement was performed by mechanical testing under compression over a period of 24 weeks, after storage in 37 °C phosphate buffer saline (PBS) solution. Furthermore, cement extracts were used to evaluate residual monomer release and the cytotoxicity of hv-LA-PMMA using fibroblastic cells. Relative to the base commercial cement, a significant reduction of Young's modulus and compressive strength of 36% and 42% was observed, respectively. Compression-tension fatigue tests at 5 MPa gave an average fatigue limit of 31,078 cycles. This was higher than another low-modulus cement and comparable to the fatigue properties of the disc annulus tissue. Monomer release tests showed that hv-LA-PMMA had a significantly higher release between 24 h and 7 days compared to the original bone cement, similarly to other low-modulus cements. Also, the control cement showed cytocompatibility at all time points of extract collection for 20-fold dilution, while hv-LA-PMMA only showed the same for extract collections at day 7. However, the 20-fold dilution was needed for both the control and the hv-LA-PMMA extracts to demonstrate more than 70% fibroblast viability at day 7. In conclusion, the mechanical testing showed promise in the use of linoleic acid in combination with a high-viscosity PMMA cement to achieve properties adequate to the application. Further testing and in vivo studies are however required to fully evaluate the mechanical performance and biocompatibility of hv-LA-PMMA for possible future clinical application.